Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease

Behavioural Brain Research

Volumn 113, Issue 1-2, 2000, Pages 121-129

  Rusted, Jennifer M ^a   Newhouse, Paul A ^b   Levin, Edward D ^c  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF VERMONT   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Animal; Attention; Human; Memory; Nicotine; Nicotinic agonists; Parkinson's disease

Indexed keywords

NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; ARTICLE; ATTENTION; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; MEMORY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; NICOTINIC AGONISTS; PARKINSON DISEASE; RECEPTORS, NICOTINIC; TREATMENT OUTCOME;

EID: 0033846169     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00207-2     Document Type: Article

References (92)

1. Arendash G.W., Sengstock G.J., Sanberg P.R., Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674:1995;252-259.
2. Arneric S.P. Basal forebrain neurons modulate cortical cerebral blood flow: increases by nicotinic cholinergic mechanisms. J. Cereb. Blood Flow Metab. 9(Suppl. 1):1989;S502.
3. Arneric S.P., Anderson D., Bannon A. et al. Preclinical pharmacology of ABT-418: a prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drugs Rev. 1:1995;1-26.
4. Aubert I., Araujo D.M., Cécyre D. et al. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:1992;529-541.
5. 3H] nicotine binding sited in human brain. J. Neurochem. 50:1988;1243-1247.
6. Buccafusco J.J., Jackson W.J., Terry A.V. Jr et al. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology. 120:1995;256-266.
7. Colrain I.M., Mangan G.L., Pellett O.L., Bates T.C. Effects of post-learning smoking on memory consolidation. Psychopharmacology. 108(4):1992;448-451.
8. Dubois B., Danze F., Pillon B. et al. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann. Neurol. 22:1987;26-30.
9. Dubois B, Pillon R, Lhermitte F, et al. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 1990;28:117-121.
10. Eriksdotter-Jönhagan M., Nordberg A., Amberla K. et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dementia, Geriatric Cognitive Disorders. 9:1998;246-257.
11. Fagerström K.O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology. 116:1994;117-119.
12. Felix R., Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience. 81:1997;1009-1017.
13. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1986;1948-1954.
14. Foulds J., Stapleton J., Feyeraband C. et al. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover design. Psychopharmacology. 106:1996;421-427.
15. Gilbert D.G., Estes S.L., Welser R. Does noise stress modulate effects of smoking/nicotine? Mood, vigilance and EEG responses. Psychopharmacology. 129:1997;382-389.
16. Gitelman D.R., Prohovnik I. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol. Aging. 13:1992;313-318.
17. Hasenfratz M., Michel C., Nil R., Battig K. Can smoking increase attention in rapid information processing during noise? Electrocortical, physiological and behavioural effects. Psychopharmacology. 98:1989;75-80.
18. Heishman S.J., Taylor R.C., Henningfield J.E. Nicotine and smoking: a review of effects on human performance. Exp. Clin. Psychopharmacol. 2:1994;355-395.
19. Hutton S., Sheppard L., Ratner H.H., Rusted J.M. Structuring the acquisition and retrieval environment to facilitate learning in individuals with dementia of the Alzheimer type. Memory. 4:1996;113-130.
20. James J.R., Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav. Genetics. 25:1995;149-159.
21. Jones G.M.M., Sahakian B.J., Levy R. et al. Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease. Psychopharmacology. 108:1992;485-494.
22. Katayama S, Hirata K, Tanaka H et al. Efficacy of transdermal nicotine in dementia: a study using event-related potentials and a middle latency response. In: Edward Domino, editor. Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, MI: NPP Books, 1995:289-302.
23. Kelton MC, Kahn HJ, Conrath CL et al. The chronic and acute effects of nicotine on Parkinson's disease. Brain Cognition. 2000;43:274-281.
24. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 13:1994;131-144.
25. LeHouezec J., Halliday R., Benowitz N.L., Callaway E., Naylor H., Herzig K. A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology. 114:1994;628-635.
26. Levin E. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417-431.
27. Levin E, Bettegowda C, Blosser J, Gordon J. AR-R 17779, an α7 nicotinic agonist improves learning and memory in rats. Behav. Pharmacol. 1999;10:675-680.
28. Levin E., Conners C., Silva D., Hinton S., Meck W., March J., Rose J. Transdermal nicotine effects on attention. Psychopharmacology. 140:1998;135-141.
29. Levin E., Kaplan S., Boardman A. Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav. Pharmacol. 8:1997;236-242.
30. Levin E., Kim P., Meray R. Chronic nicotine effects on working and reference memory in the 16-arm radial maze: interactions with D1 agonist and antagonist drugs. Psychopharmacology. 127:1996;25-30.
31. Levin E.D., Bradley A., Sigurani N. Hippocampal Nicotinic Receptors and Memory Function in Rats. 1999;Society for Research on Nicotine and Tobacco, San Diego.
32. Levin E.D., Briggs S.J., Christopher N.C., Rose J.E. Persistence of chronic nicotine-induced cognitive facilitation. Behav. Neural Biol. 58:1992;152-158.
33. Levin E.D., Briggs S.J., Christopher N.C., Rose J.E. Chronic nicotinic stimulation and blockade effects on working memory. Behav. Pharmacol. 4:1993;179-182.
34. Levin E.D., Castonguay M., Ellison G.D. Effects of the nicotinic receptor blocker, mecamylamine, on radial arm maze performance in rats. Behav. Neural Biol. 48:1987;206-212.
35. Levin E.D., Christopher N.C., Briggs S.J., Rose J.E. Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Cog. Brain Res. 1:1993;137-143.
36. Levin E.D., Christopher N.C., Weaver T., Moore J., Brucato F. Ventral hippocampal ibotenic acid lesions block chronic nicotine-induced spatial working memory improvement in rats. Cog. Brain Res. 7:1999;405-410.
37. Levin E.D., Damaj M.I., Glassco W., May E.L., Martin B.R. Bridged nicotine, isonicotine and norisonicotine effects on working memory performance of rats in the radial-arm maze. Drug Dev. Res. 46:1999;106-111.
38. Levin E.D., Lee C., Rose J.E., Reyes A., Ellison G., Jarvik M., Gritz E. Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav. Neural Biol. 53:1990;269-276.
39. Levin E.D., Rose J.E. Anticholinergic sensitivity following chronic nicotine administration as measured by radial-arm maze performance in rats. Behav. Pharmacol. 1:1990;511-520.
40. Levin E.D., Rose J.E. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Brain Res. Bull. 27:1991;125-128.
41. Levin E.D., Rose J.E., Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol. Biochem. Behav. 51:1995;369-373.
42. Levin E.D., Rose J.E., McGurk S.R., Butcher L.L. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav Neural Biol. 53:1990;103-112.
43. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology. 138:1998;217-230.
44. Levin E.D., Toll K., Chang G., Christopher N.C., Briggs S.J. Epibatidine, a potent nicotinic agonist: effects on learning and memory in the radial-arm maze. Med. Chem. Res. 6:1996;543-554.
45. Linville D.G., Arneric S.P. Cortical cerebral blood flow governed by the basal forebrain: age related impairments. Neurobiol. Aging. 12:1991;503-510.
46. Lipiello P.M., Bencherif M., Gray J.A. et al. RJR-2403: a nicotinic agonist with CNS selectivity II: in vivo characterization. J. Pharmacol. Exp. Ther. 279:1996;1422-1429.
47. Lloyd G.K., Menzaghi F., Bontempi B. et al. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 62:1998;1601-1606.
48. McGehee D.S., Heath M.J.S., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
49. Mumenthaler M.S., Taylor J.L., O'Hara R., Yesvage J.A. Influence of nicotine on simulator flight performance in non-smokers. Psychopharmacology. 140:1998;38-41.
50. Newhouse PA, Kelton M. Clinical aspects of nicotinic agents: therapeutic applications in central nervous system disorders. In: Clementi F, Gotti C, Fornasari D, editors. Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors. Heidelberg: Springer, 1999:779-812.
51. Newhouse P.A., Potter A., Corwin J. et al. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology. 108:1992;480-484.
52. Newhouse P.A., Potter A., Corwin J. et al. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 10:1994;93-107.
53. Newhouse P.A., Potter A., Corwin J. et al. Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. Drug Dev. Res. 38:1996;278-289.
54. Newhouse P.A., Potter A., Lenox R.H. et al. Effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med. Chem. Res. 2:1993;628-642.
55. Newhouse PA, Potter A, Levin ED. Nicotinic systems and Alzheimer's disease: implications for therapeutics. Drugs Aging 1997;11:206-228.
56. Newhouse P.A., Sunderland T., Tariot P.N. et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology. 95:1988;171-175.
57. Newhouse P.A., Sunderland T., Narang P.K. et al. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology. 15:1990;471-484.
58. Nordberg A. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized with PET. Acta Neurol. Scand. Suppl. 149:1993;62-65.
59. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
60. 11C-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transmission. 4:1992;79-95.
61. Perry E.K., Curtis M., Dick D.J. et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiat. 48:1985;413-421.
62. Perry E.K., Court J.A., Lloyd S. et al. b-amyloidosis in normal aging and transmitter signaling in the human temporal lobe. Ann. New York Acad. Sci. 777:1996;388-392.
63. Perry E.K., Morris C.M., Court J.A. et al. Alteration in nicotinic binding sites in Parkinson's disease, Lewy body dementia, and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
64. Pickworth W.B. Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pharmacol. Biochem. Behav. 56:1997;181-187.
65. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 1999;142:334-342.
66. Prendergrast M.A., Jackson W.J., Terry A.V. Jr, Decker M.W., Arneric S.P., Buccafusco J.J. Central nicotine receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology. 136:1998;50-58.
67. Prohovnik I., Mayeux R., Sackheim H.A. et al. Cerebral profusion as a diagnostic marker of early Alzheimer's disease. Neurology. 38:1988;931-937.
68. Provost S.C., Woodward R. Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology. 104:1991;536-540.
69. Reid W.G.J., Broe G.A., Morris J.G.L. et al. The role of cholinergic deficiency in neuropsychological deficits in idiopathic Parkinson's disease. Dementia. 3:1990;114-120.
70. Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I. The Test of Everyday Attention. Thames Valley Test Company, Bury, St. Edmonds, UK, 1994.
71. Ruberg M., Ploska F., Javoy-Agid F. et al. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res. 232:1982;129-139.
72. Rusted J.M., Eaton-Williams P. Distinguishing between attentional and amnestic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall. Psychopharmacology. 104(3):1991;363-366.
73. Rusted JM, Harrison S. Holding their attention: a comparison of laboratory and everyday concentration tasks with Alzheimer's patients. University of Sussex, 1999, unpublished report.
74. Rusted J.M., Graupner L., Warburton D.M. Effects of post-trial administration of nicotine on human memory: evaluating the conditions for improving memory. Psychopharmacology. 119:1995;405-413.
75. Rusted JM, Ratner H, Sheppard L. When all else fails, we can still make tea: a longitudinal look at activities of daily living in an Alzheimer patient. In: Conway M, Campbell R, editors. Broken Memories. Blackwell, Oxford, UK, 1995, pp 3974-410.
76. Rusted J.M., Graupner L., Tennant A., Warburton D.M. Effortful processing is a requirement for nicotine-induced improvements in memory. Psychopharmacology. 38:1998;362-368.
77. Rusted JM, Caulfield D, King L, Goode A. Moving out of the laboratory: does nicotine improve everyday attention? Submitted to Behavioural Pharmacology.
78. Rusted J.M., Warburton D.M. Nicotinic receptors and information processing. Stone T.W. CNS Neurotransmitters and Neuromodulators: Acetylcholine. 1995;185-196 CRC Press, Boca Raton, FL.
79. Sahakian B.J., Coull J.T. et al. Nicotine and THA: evidence for improved attention in patients with Dementia of the Alzheimer type. Drug. Dev. Res. 31:1994;80-88.
80. Sherwood N., Kerr J.S., Hindmarch I. Psychomotor performance in smokers following single and repeated doses of nicotine gum. Psychopharmacology. 108(4):1992;432-436.
81. Snaedal J., Johannesson T., Jonsson J.E. et al. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia. 7:1996;47-52.
82. Spilich G.J., June L., Renner J. Cigarette smoking and cognitive performance. Br. J. Addiction. 87:1992;1313-1326.
83. Vidal C. Nicotinic potentiation of glutaminergic synapses in the prefrontal cortex: new insight into analysis of the role of nicotinic receptors in cognitive functions. Drug Dev. Res. 31:1994;120-126.
84. Wang H., Fratiglioni L., Frisoni G.B., Viitanen M., Winblad B. Smoking and the occurrence of Alzheimer's disease: cross-sectional and longitudinal data in a population-based study. Am. J. Epidemiol. 149:1999;640-644.
85. Warburton D.M., Rusted J.M. Cholinergic control of cognitive resources. Neuropsychobiology. 28:1993;43-46.
86. Warpman U., Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport. 6:1995;2419-2423.
87. White H., Levin E.D. Chronic four week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology. 143:1999;158-165.
88. Whitehouse P.J., Hedreen J.C., White C.L. et al. Basal forebrain neurons in dementia of Parkinson's disease. Ann. Neurol. 13:1983;243-248.
89. Whitehouse P., Martino A., Antuono P. et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371:1986;146-151.
90. 3H] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology. 38:1988;720-723.
91. Wilson A.L., Langley L.K., Monley J. et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. 51:1995;509-514.
92. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG. Presynaptic modulation of transmitter release by nicotinic receptors. In: Nordberg A, Fuxe K, Holmstedt B, Sundwall A, editors. Progress in Brain Research. Elsevier, Amsterdam, 1989:157-163.